Lyell Immunopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lyell Immunopharma, Inc. (LYEL) on November 3, 2025, covering events occurring on October 31, 2025. The Company is a biotechnology firm incorporated in Delaware with principal executive offices in South San Francisco, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel appointments rather than financial performance.
Material Changes
On October 31, 2025, the Board of Directors made the following appointments:
- Lynn Seely, M.D. Appointed as Interim Principal Financial Officer. Dr. Seely currently serves as the Company's President, Chief Executive Officer, principal executive officer, and a director.
- Veronica Sanchez Bulis Appointed as Principal Accounting Officer. Ms. Bulis currently serves as Vice President, Corporate Controller, a role she has held since August 2021.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document is limited to the disclosure of officer appointments under Item 5.02.
Key Facts for Investor Verification
- Verify the effective date of the interim CFO appointment (October 31, 2025).
- Confirm the background of the new Principal Accounting Officer, Veronica Sanchez Bulis, including her prior experience at Sangamo Therapeutics and Core-Mark International.
- Note that the CEO, Lynn Seely, M.D., is assuming the additional interim role of Principal Financial Officer.
- Check subsequent filings for any financial data or strategic updates not included in this governance-focused report.